Fibroblasts from Patients with Idiopathic Pulmonary Fibrosis Are Resistant to Cisplatin-induced Cell Death Via Enhanced CK2-dependent XRCC1 Activity

Overview

Journal Apoptosis

Publisher Springer

Date 2019 Mar 10

PMID 30850922

Citations 10

Authors

Jintaek Im

Richard Seonghun Nho

Affiliations

Soon will be listed here.

Abstract

Idiopathic pulmonary fibrosis (IPF) is a deadly and progressive fibrotic lung disease, but the precise etiology remains elusive. IPF is characterized by the presence of apoptosis-resistant (myo)fibroblasts that relentlessly produce a collagen-rich extracellular matrix (ECM). Recent studies showed that an anti-cancer chemotherapy drug cisplatin is implicated in the development of pulmonary fibrosis, suggesting that the treatment of cancer patients with cisplatin may alter fibroblast viability. To address this possibility, we investigated the cisplatin-induced cell death mechanism in lung fibroblasts derived from IPF and non-IPF patients in response to a collagen matrix. IPF fibroblasts showed enhanced resistance to cisplatin-induced cell death compared to non-IPF fibroblasts in a time- and dose-dependent manner. Molecular study showed that the expression of γH2AX, PUMA and caspase-3/7 activity was abnormally reduced in IPF fibroblasts, suggesting that DNA damage-induced apoptosis caused by cisplatin was suppressed in IPF fibroblasts. Our study further revealed that DNA repair protein XRCC1 activity was aberrantly increased as a result of CK2 hyper-activation in cisplatin-treated IPF fibroblasts, and this alteration protected IPF fibroblasts from cisplatin-induced cell death. Our results showed that IPF fibroblasts residing in a collagen rich matrix are resistance to cisplatin-induced cell death due to the aberrantly high CK2/XRCC1-dependent DNA repair activity. This finding suggests that pulmonary fibrosis may develop and worsen due to the presence of apoptosis-resistant lung fibroblasts in cisplatin-treated cancer patients.

Citing Articles

The aged extracellular matrix and the profibrotic role of senescence-associated secretory phenotype.

Mebratu Y, Soni S, Rosas L, Rojas M, Horowitz J, Nho R Am J Physiol Cell Physiol. 2023; 325(3):C565-C579.

PMID: 37486065 PMC: 10511170. DOI: 10.1152/ajpcell.00124.2023.

The Role of DNA Damage and Repair in Idiopathic Pulmonary Fibrosis.

Zhu J, Liu L, Ma X, Cao X, Chen Y, Qu X Antioxidants (Basel). 2022; 11(11).

PMID: 36421478 PMC: 9687113. DOI: 10.3390/antiox11112292.

Functional Repercussions of Hypoxia-Inducible Factor-2α in Idiopathic Pulmonary Fibrosis.

Torres-Soria A, Romero Y, Balderas-Martinez Y, Velazquez-Cruz R, Torres-Espindola L, Camarena A Cells. 2022; 11(19).

PMID: 36230900 PMC: 9562026. DOI: 10.3390/cells11192938.

Fibrous stroma: Driver and passenger in cancer development.

Sharma V, Letson J, Furuta S Sci Signal. 2022; 15(724):eabg3449.

PMID: 35258999 PMC: 8988932. DOI: 10.1126/scisignal.abg3449.

Identifying potential novel insights for COVID-19 pathogenesis and therapeutics using an integrated bioinformatics analysis of host transcriptome.

El-Aarag S, Mahmoud A, ElHefnawi M Int J Biol Macromol. 2021; 194:770-780.

PMID: 34826456 PMC: 8610562. DOI: 10.1016/j.ijbiomac.2021.11.124.

References

Im J, Lawrence J, Seelig D, Nho R . FoxM1-dependent RAD51 and BRCA2 signaling protects idiopathic pulmonary fibrosis fibroblasts from radiation-induced cell death. Cell Death Dis. 2018; 9(6):584. PMC: 5964221. DOI: 10.1038/s41419-018-0652-4. View

Bonner W, Redon C, Dickey J, Nakamura A, Sedelnikova O, Solier S . GammaH2AX and cancer. Nat Rev Cancer. 2008; 8(12):957-67. PMC: 3094856. DOI: 10.1038/nrc2523. View

Lee K, Im J, Shibata E, Dutta A . ASF1a Promotes Non-homologous End Joining Repair by Facilitating Phosphorylation of MDC1 by ATM at Double-Strand Breaks. Mol Cell. 2017; 68(1):61-75.e5. PMC: 5743198. DOI: 10.1016/j.molcel.2017.08.021. View

Xu W, Wang S, Chen Q, Zhang Y, Ni P, Wu X . TXNL1-XRCC1 pathway regulates cisplatin-induced cell death and contributes to resistance in human gastric cancer. Cell Death Dis. 2014; 5:e1055. PMC: 3944244. DOI: 10.1038/cddis.2014.27. View

Parsons J, Dianova I, Finch D, Tait P, Strom C, Helleday T . XRCC1 phosphorylation by CK2 is required for its stability and efficient DNA repair. DNA Repair (Amst). 2010; 9(7):835-41. DOI: 10.1016/j.dnarep.2010.04.008. View

Gay S, Kazerooni E, Toews G, Lynch 3rd J, Gross B, Cascade P . Idiopathic pulmonary fibrosis: predicting response to therapy and survival. Am J Respir Crit Care Med. 1998; 157(4 Pt 1):1063-72. DOI: 10.1164/ajrccm.157.4.9703022. View

Ryu J, Colby T, Hartman T . Idiopathic pulmonary fibrosis: current concepts. Mayo Clin Proc. 1998; 73(11):1085-101. DOI: 10.4065/73.11.1085. View

Mills P, Husband J . Computed tomography of pulmonary bleomycin toxicity. Semin Ultrasound CT MR. 1990; 11(5):417-22. View

Lan L, Nakajima S, Oohata Y, Takao M, Okano S, Masutani M . In situ analysis of repair processes for oxidative DNA damage in mammalian cells. Proc Natl Acad Sci U S A. 2004; 101(38):13738-43. PMC: 518826. DOI: 10.1073/pnas.0406048101. View

10.

Tian W, Rojo de la Vega M, Schmidlin C, Ooi A, Zhang D . Kelch-like ECH-associated protein 1 (KEAP1) differentially regulates nuclear factor erythroid-2-related factors 1 and 2 (NRF1 and NRF2). J Biol Chem. 2017; 293(6):2029-2040. PMC: 5808764. DOI: 10.1074/jbc.RA117.000428. View

11.

Nho R, Hergert P . IPF fibroblasts are desensitized to type I collagen matrix-induced cell death by suppressing low autophagy via aberrant Akt/mTOR kinases. PLoS One. 2014; 9(4):e94616. PMC: 3984186. DOI: 10.1371/journal.pone.0094616. View

12.

Nho R . Alteration of Aging-Dependent MicroRNAs in Idiopathic Pulmonary Fibrosis. Drug Dev Res. 2015; 76(7):343-53. PMC: 4615542. DOI: 10.1002/ddr.21272. View

13.

Jordan P, Carmo-Fonseca M . Molecular mechanisms involved in cisplatin cytotoxicity. Cell Mol Life Sci. 2000; 57(8-9):1229-35. PMC: 11147023. DOI: 10.1007/pl00000762. View

14.

Ohe Y, Yamamoto S, Suzuki K, Hojo F, Kakinuma R, Matsumoto T . Risk factors of treatment-related death in chemotherapy and thoracic radiotherapy for lung cancer. Eur J Cancer. 2001; 37(1):54-63. DOI: 10.1016/s0959-8049(00)00350-6. View

15.

Sirica A . The role of cancer-associated myofibroblasts in intrahepatic cholangiocarcinoma. Nat Rev Gastroenterol Hepatol. 2011; 9(1):44-54. DOI: 10.1038/nrgastro.2011.222. View

16.

Lazo J, Hoyt D . The molecular basis of interstitial pulmonary fibrosis caused by antineoplastic agents. Cancer Treat Rev. 1990; 17(2-3):165-7. DOI: 10.1016/0305-7372(90)90042-e. View

17.

Wilson M, Wynn T . Pulmonary fibrosis: pathogenesis, etiology and regulation. Mucosal Immunol. 2009; 2(2):103-21. PMC: 2675823. DOI: 10.1038/mi.2008.85. View

18.

Wadey K, Brown B, Sala-Newby G, Jayaraman P, Gaston K, George S . Protein kinase CK2 inhibition suppresses neointima formation via a proline-rich homeodomain-dependent mechanism. Vascul Pharmacol. 2017; 99:34-44. PMC: 5718878. DOI: 10.1016/j.vph.2017.09.004. View

19.

Campalans A, Marsin S, Nakabeppu Y, OConnor T, Boiteux S, Radicella J . XRCC1 interactions with multiple DNA glycosylases: a model for its recruitment to base excision repair. DNA Repair (Amst). 2005; 4(7):826-35. DOI: 10.1016/j.dnarep.2005.04.014. View

20.

Rabinowits M, Souhami L, Gil R, Andrade C, Paiva H . Increased pulmonary toxicity with bleomycin and cisplatin chemotherapy combinations. Am J Clin Oncol. 1990; 13(2):132-8. DOI: 10.1097/00000421-199004000-00009. View